8-K filings, Oct 29, 2026: Caterpillar reports 38% profit rise; Gilead HIV sales up 18%

Caterpillar, Gilead and Altria reported higher profit or sales for the third quarter of 2026

These results come from Form 8-K filings, the filings a US company makes to report a material event.

• Caterpillar said profit in its Power & Energy segment rose $510 million, or 31%, mainly due to higher sales volume.
• Gilead Sciences said sales of its human immunodeficiency virus (HIV) products rose 18% to $6.2 billion. It cited higher realized prices, HIV prevention demand and favorable inventory dynamics.
• Gilead said Biktarvy sales rose 10% to $4.1 billion and Descovy sales rose 49% to $1.0 billion.
• Altria said its adjusted diluted earnings per share (EPS), its profit per share on its own adjusted basis, rose 4.8% to $1.52. It said net revenues rose 1.0% to $6.1 billion.

Several companies described large investments in the United States

• Gilead said its new Research Center is the first of three projects supporting a $32 billion U.S. research, development and manufacturing investment through 2030.
• Bristol Myers Squibb said its multi-modal campus represents an approximately $2.3 billion investment. It said the campus is expected to create nearly 500 skilled jobs.
• Amazon said it will invest more than $1.5 billion to raise starting pay for U.S. full-time operations employees to $20 an hour and add benefits. It also introduced a $1 billion investment in U.S. data center communities.
• Intel said it completed a $23 billion public equity offering to support future growth.

Drugmakers reported trial results, approvals and higher costs

• Eli Lilly said retatrutide delivered more than double the weight loss of Ozempic's highest approved dose in a head-to-head trial. It said marketing, selling and administrative expenses rose 14% to $3.1 billion.
• Bristol Myers Squibb said the Food and Drug Administration (FDA) approved Camzyos for symptomatic obstructive hypertrophic cardiomyopathy. It recorded $1.6 billion in acquired in-process research and development charges.
• Merck said purchase timing contributed approximately $550 million to its sales growth.

Other companies reported a weaker personal computer outlook and mixed results

• Intel said it expects the personal computer (PC) slowdown to continue through at least the first half of next year.
• Mastercard said its operating expenses rose 11%, primarily due to higher general and administrative expenses.
• Starbucks said its consolidated net revenues for the fourth quarter of 2026 declined, primarily because it converted its China retail operations to a licensed joint venture model.
• Sandisk announced an eight-for-one forward stock split in its filing for the first quarter of fiscal year 2027.